MARKET

PRLD

PRLD

Prelude Therapeutics Inc
NASDAQ
3.545
+0.455
+14.72%
Opening 15:53 03/10 EDT
OPEN
2.990
PREV CLOSE
3.090
HIGH
3.640
LOW
2.990
VOLUME
386.72K
TURNOVER
--
52 WEEK HIGH
4.220
52 WEEK LOW
0.6101
MARKET CAP
222.86M
P/E (TTM)
-2.4099
1D
5D
1M
3M
1Y
5Y
1D
Prelude Therapeutics Reports 2025 Results, Highlights JAK2 Program
TipRanks · 9h ago
Prelude Therapeutics Earnings Report: Q4 Overview
Benzinga · 11h ago
Prelude Therapeutics GAAP EPS of -$1.29 misses by $0.04, revenue of $12.14M
Seeking Alpha · 11h ago
Prelude Therapeutics FY2025 net loss fell 22% to USD 99.5 million
Reuters · 11h ago
Prelude Therapeutics reports FY25 EPS ($1.29) vs. ($1.68) last year
TipRanks · 11h ago
Prelude Therapeutics sees cash runway into 2Q27
TipRanks · 11h ago
*Prelude Therapeutics 2025 Rev $12.1M Vs. $7M >PRLD
Dow Jones · 11h ago
Prelude Therapeutics reports $99.5 mln net loss for 2025
Reuters · 11h ago
More
About PRLD
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.

Webull offers Prelude Therapeutics Inc stock information, including NASDAQ: PRLD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRLD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRLD stock methods without spending real money on the virtual paper trading platform.